J Galceran1,2, A Ameijide3, M Carulla3, A Mateos4, J R Quirós5, D Rojas6, A Alemán7, A Torrella8, M Chico9, M Vicente10, J M Díaz11, N Larrañaga12,13, R Marcos-Gragera14,15, M J Sánchez13,16,17, J Perucha18, P Franch19, C Navarro13,20,21, E Ardanaz13,22, J Bigorra3, P Rodrigo23, R Peris Bonet24. 1. Tarragona Cancer Registry, Fundation Society for Cancer Research and Prevention (FUNCA), Pere Virgili Health Research Institute (IISPV), Reus, Spain. jgalceran@grupsagessa.com. 2. University Rovira i Virgili, Reus, Spain. jgalceran@grupsagessa.com. 3. Tarragona Cancer Registry, Fundation Society for Cancer Research and Prevention (FUNCA), Pere Virgili Health Research Institute (IISPV), Reus, Spain. 4. Albacete Cancer Registry, Health and Social Welfare Authority, Castile-La Mancha, Spain. 5. Asturias Cancer Registry, Public Health Directorate, Department of Health, Asturias, Spain. 6. Canary Islands Cancer Registry (Gran Canaria), Public Health Directorate, Canary Islands Government, Las Palmas de Gran Canaria, Spain. 7. Canary Islands Cancer Registry (Tenerife), Public Health Directorate, Canary Islands Government, Tenerife, Spain. 8. Castellón Cancer Registry, Public Health Directorate, Valencian Government, Castellón, Spain. 9. Ciudad Real Cancer Registry, Health and Social Welfare Authority, Castile-La Mancha, Spain. 10. C. Valenciana Childhood Cancer Registry, Public Health Directorate, Valencian Government, Valencia, Spain. 11. Cuenca Cancer Registry, Health and Social Welfare Authority, Castile-La Mancha, Spain. 12. Basque Country Cancer Registry, Health Department, Basque Government, Vitoria-Gasteiz, Spain. 13. CIBER of Epidemiology and Public Health (CIBERESP), Madrid, Spain. 14. Epidemiology Unit and Girona Cancer Registry (UERCG), Oncology Coordination Plan (PDO), Department of Health, Autonomous Government of Catalonia, Descriptive Epidemiology, Genetics and Cancer Prevention Group [Girona Biomedical Research Institute] IDIBGI, Catalan Institute of Oncology-Girona (ICO), Girona, Spain. 15. University of Girona (UdG), Girona, Spain. 16. Registro de Cáncer de Granada, Escuela Andaluza de Salud Pública, Instituto de Investigación Biosanitaria ibs.GRANADA, Hospitales Universitarios de Granada/Universidad de Granada, Granada, Spain. 17. Hospitales Universitarios de Granada/Universidad de Granada, Granada, Spain. 18. La Rioja Cancer Registry, Epidemiology and Health Prevention Service, Logroño, Spain. 19. Mallorca Cancer Registry, Public Health and Participation Department, Palma de Mallorca, Spain. 20. Department of Epidemiology, Murcia Regional Health Council, IMIB-Arrixaca, Murcia, Spain. 21. Department of Health and Social Sciences, Universidad de Murcia, Murcia, Spain. 22. Navarre Cancer Registry, Navarre Public Health Institute, IdiSNA, Navarra Institute for Health Research, Pamplona, Spain. 23. Zaragoza Cancer Registry, Aragon Health Science Institute, Saragossa, Spain. 24. Spanish Childhood Cancer Registry, Spanish Society of Paediatric Haematology and Oncology, University of Valencia, Valencia, Spain.
Abstract
PURPOSE: Periodic cancer incidence estimates of Spain from all existing population-based cancer registries at any given time are required. The objective of this study was to present the current situation of cancer incidence in Spain. METHODS: The Spanish Network of Cancer Registries (REDECAN) estimated the numbers of new cancer cases occurred in Spain in 2015 by applying the incidence-mortality ratios method. In the calculus, incidence data from population-based cancer registries and mortality data of all Spain were used. RESULTS: In 2015, nearly a quarter of a million new invasive cancer cases were diagnosed in Spain, almost 149,000 in men (60.0%) and 99,000 in women. Globally, the five most common cancers were those of colon-rectum, prostate, lung, breast and urinary bladder. By gender, the four most common cancers in men were those of prostate (22.4%), colon-rectum (16.6%), lung (15.1%) and urinary bladder (11.7%). In women, the most common ones were those of breast (28.0%), colon-rectum (16.9%), corpus uteri (6.2%) and lung (6.0%). In recent years, cancer incidence in men seems to have stabilized due to the fact that the decrease in tobacco-related cancers compensates for the increase in other types of cancer like those of colon and prostate. In women, despite the stabilization of breast cancer incidence, increased incidence is due, above all, to the rise of colorectal and tobacco-related cancers. CONCLUSION: To reduce these incident cancer cases, improvement of smoking control policies and extension of colorectal cancer screening should be the two priorities in cancer prevention for the next years.
PURPOSE: Periodic cancer incidence estimates of Spain from all existing population-based cancer registries at any given time are required. The objective of this study was to present the current situation of cancer incidence in Spain. METHODS: The Spanish Network of Cancer Registries (REDECAN) estimated the numbers of new cancer cases occurred in Spain in 2015 by applying the incidence-mortality ratios method. In the calculus, incidence data from population-based cancer registries and mortality data of all Spain were used. RESULTS: In 2015, nearly a quarter of a million new invasive cancer cases were diagnosed in Spain, almost 149,000 in men (60.0%) and 99,000 in women. Globally, the five most common cancers were those of colon-rectum, prostate, lung, breast and urinary bladder. By gender, the four most common cancers in men were those of prostate (22.4%), colon-rectum (16.6%), lung (15.1%) and urinary bladder (11.7%). In women, the most common ones were those of breast (28.0%), colon-rectum (16.9%), corpus uteri (6.2%) and lung (6.0%). In recent years, cancer incidence in men seems to have stabilized due to the fact that the decrease in tobacco-related cancers compensates for the increase in other types of cancer like those of colon and prostate. In women, despite the stabilization of breast cancer incidence, increased incidence is due, above all, to the rise of colorectal and tobacco-related cancers. CONCLUSION: To reduce these incident cancer cases, improvement of smoking control policies and extension of colorectal cancer screening should be the two priorities in cancer prevention for the next years.
Entities:
Keywords:
Cancer; Cancer cases; Cancer statistics; Incidence; Spain; Trends
Authors: Frederike L Büchner; H Bas Bueno-de-Mesquita; Martine M Ros; Kim Overvad; Christina C Dahm; Louise Hansen; Anne Tjønneland; Françoise Clavel-Chapelon; Marie-Christine Boutron-Ruault; Marina Touillaud; Rudolf Kaaks; Sabine Rohrmann; Heiner Boeing; Ute Nöthlings; Antonia Trichopoulou; Dimosthenis Zylis; Vardis Dilis; Domenico Palli; Sabina Sieri; Paolo Vineis; Rosario Tumino; Salvatore Panico; Petra H M Peeters; Carla H van Gils; Eiliv Lund; Inger T Gram; Tonje Braaten; María-José Sánchez; Antonio Agudo; Nerea Larrañaga; Eva Ardanaz; Carmen Navarro; Marcial V Argüelles; Jonas Manjer; Elisabet Wirfält; Göran Hallmans; Torgny Rasmuson; Tim J Key; Kay-Tee Khaw; Nick Wareham; Nadia Slimani; Anne-Claire Vergnaud; Wei W Xun; Lambertus A L M Kiemeney; Elio Riboli Journal: Cancer Epidemiol Biomarkers Prev Date: 2010-08-31 Impact factor: 4.254
Authors: Frederik Hvid-Jensen; Lars Pedersen; Asbjørn Mohr Drewes; Henrik Toft Sørensen; Peter Funch-Jensen Journal: N Engl J Med Date: 2011-10-13 Impact factor: 91.245
Authors: J Ferlay; E Steliarova-Foucher; J Lortet-Tieulent; S Rosso; J W W Coebergh; H Comber; D Forman; F Bray Journal: Eur J Cancer Date: 2013-02-26 Impact factor: 9.162
Authors: A Fondevilla Soler; J L López-Guerra; A García Fernández; M A Samaniego Conde; M J Belmonte González; J M Praena-Fernandez; E Rivin Del Campo; M Alcaraz; I Azinovic Journal: Clin Transl Oncol Date: 2018-11-30 Impact factor: 3.405
Authors: Mercè Grau-Pérez; Gregorio Carretero; Pablo Almeida; Elena Castro-González; María Del Pilar de-la-Rosa-Del-Rey; Jesús María González-Martín; Leopoldo Borrego Journal: Cancer Causes Control Date: 2021-03-01 Impact factor: 2.506
Authors: J Masià; Á Merchán-Galvis; K Salas; C Requeijo; E Cánovas; M J Quintana; X Bonfill Journal: Clin Transl Oncol Date: 2019-07-20 Impact factor: 3.405
Authors: M Lázaro; B P Valderrama; C Suárez; G de-Velasco; C Beato; I Chirivella; A González-Del-Alba; N Laínez; M J Méndez-Vidal; J A Arranz Journal: Clin Transl Oncol Date: 2020-01-28 Impact factor: 3.405
Authors: Ana Isabel Cobo-Cuenca; Noelia María Martín-Espinosa; María Aurora Rodríguez-Borrego; Juan Manuel Carmona-Torres Journal: Qual Life Res Date: 2018-10-15 Impact factor: 4.147
Authors: F Bautista; A Cañete; G L Ramírez-Villar; J M Fernández; J L Fuster; C Diaz de Heredia; I Astigarraga; M García-Ariza; S Rives; J L Dapena; C Márquez; A Molinés; M Del M Bermúdez; S Gallego; M Del M Andrés; J Verdu-Amoros; C Hernández; M López; A Catalá; Á Lassaletta; O Cruz; M Ramírez; F Lendínez; A Carboné; J Gomez Sirvent; M Tallón; T Acha; L Moreno; A Fernández-Teijeiro Journal: Clin Transl Oncol Date: 2019-10-09 Impact factor: 3.405
Authors: M Rodríguez-Barranco; E Salamanca-Fernández; M L Fajardo; E Bayo; Y-L Chang-Chan; J Expósito; C García; J Tallón; P Minicozzi; M Sant; D Petrova; M A Luque-Fernandez; M-J Sánchez Journal: Clin Transl Oncol Date: 2018-10-19 Impact factor: 3.405
Authors: Ángel Borque-Fernando; Luis Mariano Esteban; Ana Celma; Sarai Roche; Jacques Planas; Lucas Regis; Inés de Torres; Maria Eugenia Semidey; Enrique Trilla; Juan Morote Journal: World J Urol Date: 2019-09-10 Impact factor: 4.226
Authors: Mª D Torregrosa; M J Escudero; I Paredero; E Carrasco; B Bermejo; J Gavila; J García-Saenz; A Santaballa; P Martínez; A Llombart; R Andrés; N Batista; A Fernández; A Antón; M Seguí; S Gonzalez; A Ruiz Journal: Clin Transl Oncol Date: 2019-08-05 Impact factor: 3.405
Authors: Elena Salamanca-Fernández; Miguel Rodriguez-Barranco; Yoe-Ling Chang-Chan; Daniel Redondo-Sánchez; Santiago Domínguez-López; Eloísa Bayo; Dariusz Narankiewicz; José Expósito; María José Sánchez Journal: Endocrine Date: 2018-07-24 Impact factor: 3.633